Vertex execs whip up a cheer from the analysts after hedging their bet by picking their two top triples for PhIII
Vertex mapped out its late-stage strategy for a new triple therapy for cystic fibrosis on Wednesday evening, earning considerable applause from an appreciative group of analysts covering the biotech.
The biotech’s $VRTX executive team has stoked blockbuster hopes around these combination studies, key to their plan to broaden the scope of patients they can cover, and they did their best to keep expectations high as rivals look to carve into the market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
